Patient ID | Stage | Sample | CA (BM aspirates) | IHC (BM biopsies) | MFC (BM aspirates) | ||||
% of cells | Number of cells | CD56 (MFI) | GD2 (MFI) | B7-H3 (MFI) | |||||
4904 | Onset | LIC | Positive (3+) | NA | 0.178787 | 708/396,000 | + (46,177) | + (118,874) | + (17,282) |
4908 | Onset | RIC | Negative | NA | 0.000000 | 0/260,000 | ND | ND | ND |
LIC | Positive (1+) | NA | 0.000000 | 0/312,000 | ND | ND | ND | ||
4914 | Onset | RIC | Positive (1.5+) | NA | 0.012612 | 28/222,000 | + (91,064) | + (15,574) | + (40,217) |
LIC | 1 cluster/3 smears | NA | 0.000000 | 0/158,600 | ND | ND | ND | ||
4650 | Relapse | RIC | Negative | NA | 0.000000 | 0/159,260 | ND | ND | ND |
LIC | Negative | NA | 0.000000 | 0/155,194 | ND | ND | ND | ||
4929 | Onset | RT | Negative | NA | 0.000000 | 0/94,349 | ND | ND | ND |
4930 | Onset | RIC | Positive (2.5+) | NA | 4,162,255 | 3710/89,128 | + (73,126) | + (44,163) | + (46,870) |
LIC | Positive (1.5+) | NA | 6,515,205 | 2753/42,255 | + (78,511) | + (51,644) | + (41,537) | ||
4932 | Onset | LIC | Negative | NA | 0.000379 | 1/263,301 | + | – | + |
4814 | Off-therapy | RIC | Negative | NTI | 0.000261 | 1/381,961 | + | – | + |
LIC | Negative | NTI | 0.000265 | 1/376,421 | + | – | + | ||
4547 | Off-therapy | RIC | Negative | NTI | 0.000000 | 0/375,000 | ND | ND | ND |
LIC | Negative | NTI | 0.000267 | 1/374,494 | + | – | + | ||
4668 | Relapse | RIC | Negative | NA | 0.00025 | 1/400,000 | + | – | + |
LIC | Negative | NA | 0.00075 | 3/400,000 | + | – | + |
The total number of cells acquired for each sample, number and percentages of CD45neg CD56pos cells (gated on FSC>50,000 syto16+ cells) are indicated. MFI of CD56, GD2 and B7-H3 molecules are in parentheses. CA scores are indicated.
BM, bone marrow; CA, cytomorphological analysis; IHC, immunohistochemistry performed on BM trephine biopsies; LIC, left iliac crest; MFI, mean fluorescence intensity ; NA, not available; ND, not determined; NTI, not tumor identified by means of morphology and immunohistochemistry; RIC, right iliac crest.